$531 Million is the total value of BVF INC/IL's 29 reported holdings in Q3 2016. The portfolio turnover from Q2 2016 to Q3 2016 was 50.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BPMC | Sell | BLUEPRINT MEDICINES CORP | $82,123,000 | +40.1% | 2,765,080 | -4.5% | 15.48% | +23.9% |
| CCXI | Sell | CHEMOCENTRYX INC | $48,707,000 | +32.6% | 8,064,019 | -1.4% | 9.18% | +17.3% |
| CYTK | Buy | CYTOKINETICS INC | $45,873,000 | -3.1% | 4,997,071 | +0.2% | 8.64% | -14.3% |
| ARRY | Sell | ARRAY BIOPHARMA INC | $43,613,000 | +48.3% | 6,461,186 | -21.8% | 8.22% | +31.2% |
| CASC | CASCADIAN THERAPEUTICS INC | $30,831,000 | +73.9% | 18,799,368 | 0.0% | 5.81% | +53.8% | |
| FWP | Sell | FORWARD PHARMA A/Ssponsored adr | $29,145,000 | +12.6% | 1,387,853 | -2.6% | 5.49% | -0.4% |
| CLCD | New | COLUCID PHARMACEUTICALS INC | $29,120,000 | – | 763,300 | +100.0% | 5.49% | – |
| CNCE | Sell | CONCERT PHARMACEUTICALS INC | $27,532,000 | -11.0% | 2,723,210 | -1.2% | 5.19% | -21.3% |
| XENE | Buy | XENON PHARMACEUTICALS INC | $25,182,000 | +139.6% | 3,108,905 | +75.1% | 4.74% | +111.9% |
| OMED | Buy | ONCOMED PHARMACEUTICALS INC | $20,711,000 | +25.6% | 1,812,005 | +35.3% | 3.90% | +11.1% |
| GLYC | Sell | GLYCOMIMETICS INC | $17,348,000 | -2.5% | 2,426,282 | -0.9% | 3.27% | -13.8% |
| CTIC | CTI BIOPHARMA CORP | $16,767,000 | +10.1% | 44,796,940 | 0.0% | 3.16% | -2.6% | |
| TBRA | Sell | TOBIRA THERAPEUTICS INC | $15,873,000 | +0.8% | 399,433 | -68.1% | 2.99% | -10.8% |
| NVLS | Sell | NIVALIS THERAPEUTICS INC | $13,900,000 | +56.8% | 1,709,673 | -11.3% | 2.62% | +38.7% |
| ARQL | Sell | ARQULE INC | $13,246,000 | -6.4% | 7,400,128 | -0.7% | 2.50% | -17.2% |
| CTMX | Sell | CYTOMX THERAPEUTICS INC | $9,280,000 | +49.9% | 591,813 | -2.4% | 1.75% | +32.6% |
| IMDZ | New | IMMUNE DESIGN CORP | $9,096,000 | – | 1,200,000 | +100.0% | 1.71% | – |
| GTXI | GTX INC DEL | $9,014,000 | +42.4% | 11,512,000 | 0.0% | 1.70% | +25.9% | |
| INFI | Sell | INFINITY PHARMACEUTICALS INC | $8,033,000 | +16.5% | 5,149,644 | -0.7% | 1.51% | +3.1% |
| PTGX | New | PROTAGONIST THERAPEUTICS INC | $7,924,000 | – | 375,000 | +100.0% | 1.49% | – |
| ESPR | Sell | ESPERION THERAPEUTICS INC NE | $6,840,000 | +38.7% | 493,872 | -1.1% | 1.29% | +22.6% |
| ADRO | Sell | ADURO BIOTECH INC | $6,229,000 | +7.2% | 501,155 | -2.4% | 1.17% | -5.2% |
| SNSS | New | SUNESIS PHARMACEUTICALS INC | $3,192,000 | – | 730,361 | +100.0% | 0.60% | – |
| New | OREXIGEN THERAPEUTICS INCnote 2.750%12/0 | $2,650,000 | – | 10,000,000 | +100.0% | 0.50% | – | |
| OREXQ | New | OREXIGEN THERAPEUTICS INC | $2,440,000 | – | 734,976 | +100.0% | 0.46% | – |
| PTIE | Buy | PAIN THERAPEUTICS INC | $2,278,000 | -51.6% | 2,278,552 | +6.0% | 0.43% | -57.2% |
| PIRS | Buy | PIERIS PHARMACEUTICALS INC | $1,858,000 | +377.6% | 1,016,593 | +321.2% | 0.35% | +321.7% |
| CBIO | Sell | CATALYST BIOSCIENCES INC | $1,048,000 | -29.0% | 865,773 | -10.8% | 0.20% | -37.3% |
| GBIM | GLOBEIMMUNE INC | $822,000 | -35.6% | 657,653 | 0.0% | 0.16% | -43.0% | |
| AVIR | Exit | AVIRAGEN THERAPEUTICS INC | $0 | – | -208,353 | -100.0% | -0.06% | – |
| CALA | Exit | CALITHERA BIOSCIENCES INC | $0 | – | -121,400 | -100.0% | -0.10% | – |
| MSTX | Exit | MAST THERAPEUTICS INC | $0 | – | -3,696,961 | -100.0% | -0.37% | – |
| OREX | Exit | OREXIGEN THERAPEUTICS INC | $0 | – | -5,252,100 | -100.0% | -0.48% | – |
| SNSS | Exit | SUNESIS PHARMACEUTICALS INC | $0 | – | -4,813,294 | -100.0% | -0.56% | – |
| QLTI | Exit | QLT INC | $0 | – | -2,255,476 | -100.0% | -0.68% | – |
| MGNX | Exit | MACROGENICS INC | $0 | – | -200,000 | -100.0% | -1.15% | – |
| PRTK | Exit | PARATEK PHARMACEUTICALS INC | $0 | – | -575,000 | -100.0% | -1.70% | – |
| VTAE | Exit | VITAE PHARMACEUTICALS INC | $0 | – | -761,079 | -100.0% | -1.75% | – |
| IONS | Exit | IONIS PHARMACEUTICALS INC | $0 | – | -850,000 | -100.0% | -4.22% | – |
| Exit | EXELIXIS INCnote 4.250% 8/1 | $0 | – | -22,822,778 | -100.0% | -7.23% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 36 | Q3 2023 | 4.7% |
| PIERIS PHARMACEUTICALS INC | 30 | Q3 2023 | 2.8% |
| CYTOKINETICS INC | 29 | Q4 2020 | 11.8% |
| INFINITY PHARMACEUTICALS INC | 29 | Q2 2023 | 4.3% |
| XOMA CORP DEL | 28 | Q3 2023 | 7.3% |
| ARQULE INC | 27 | Q4 2019 | 4.8% |
| CHEMOCENTRYX INC | 26 | Q3 2019 | 13.8% |
| CYTOMX THERAPEUTICS INC | 26 | Q3 2023 | 5.3% |
| CORVUS PHARMACEUTICALS INC | 26 | Q3 2023 | 2.3% |
| ARRAY BIOPHARMA INC | 25 | Q2 2019 | 14.5% |
View BVF INC/IL's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 4 | 2024-01-29 |
| 3 | 2024-01-26 |
| 4 | 2024-01-09 |
| 4 | 2023-12-20 |
| 4 | 2023-11-17 |
| 13F-HR | 2023-11-14 |
| 3 | 2023-11-13 |
| 3 | 2023-11-06 |
| 4 | 2023-11-06 |
View BVF INC/IL's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.